Measuring urine S1P to detect overactive bladder in people with multiple sclerosis
Official title: Prospective Study Evaluating the Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis
Run by University Hospital, Toulouse · NCT06161376 · Data updated 2026-11-12
We will test whether measuring a urine molecule called sphingosine 1-phosphate (S1P) can indicate bladder overactivity in people with multiple sclerosis who are undergoing urodynamic testing.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | December 4, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT06161376 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are French residents with multiple sclerosis who are enrolled in the social security system and are scheduled for urodynamic testing without active urinary infection or exclusionary pelvic/bladder conditions.
✕Probably not a fit
Patients with anatomical subvesical obstruction, urothelial carcinoma, interstitial cystitis, prior augmentation cystoplasty, untreated urinary tract infection, or those not undergoing urodynamic testing are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will measure urinary S1P levels in French patients with multiple sclerosis who are scheduled for urodynamic evaluation at Toulouse University Hospital. Urine samples will be collected and analyzed for S1P and compared with simultaneous urodynamic measurements of detrusor activity. Patients with active urinary tract infection, pregnancy, legal guardianship restrictions, or specific pelvic/bladder conditions are excluded. The aim is to confirm whether urinary S1P correlates with invasive urodynamic findings and could serve as a noninvasive biomarker.
Why it matters
Potential benefit: If successful, a urine S1P test could provide a noninvasive way to detect detrusor overactivity and reduce reliance on invasive urodynamic testing.
How similar studies have gone: Preliminary work at Toulouse University Hospital suggests a link between urinary S1P and detrusor activity, but this biomarker has not yet been validated in larger or multicenter cohorts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * French residents enrolled in the social security system * Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not * Patients scheduled for urodynamic assessment as part of their management Exclusion criteria: * Pregnant or lactating females * Patients under legal guardianship * Untreated urinary tract infection at the time of inclusion * Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty
Where it's running
-
Toulouse Hospital
Toulouse, France Recruiting
Study contacts
- Principal investigator: Xavier Game, MD — University Hospital, Toulouse
- Study coordinator: Xavier Game, MD
- Email: game.x@chu-toulouse.fr
- Phone: 05 61 32 33 01
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.